ArticleBlood cancer journal2018
Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms.
Article in Blood cancer journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- [Chinese guidelines on the diagnosis and treatment of adult essential thrombocythemia (2026)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Guideline
- A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms.Blood advances · 2021Pooled it
- Review
- What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?Hematology. American Society of Hematology. Education Program · 2024Article
- Cancer-associated thrombosis in hematologic malignancies.International journal of hematology · 2024Review
- Management of classical Philadelphia chromosome-negative myeloproliferative neoplasms in Asia: consensus of the Asian Myeloid Working Group.Clinical and experimental medicine · 2023Review
- Cerebral venous thrombosis in patients with autoimmune disease, hematonosis or coronavirus disease 2019: Many familiar faces and some strangers.CNS neuroscience & therapeutics · 2023Review
- Endovascular treatment for severe cerebral venous sinus thrombosis in a patient with polycythemia vera and nephrotic syndrome: a case report.American journal of translational research · 2023Article
- Diagnosis and Management of Cardiovascular Risk in Patients with Polycythemia Vera.Vascular health and risk management · 2023Review
- Site-specific venous thrombosis in essential thrombocythemia: Impact on subsequent vascular events and survival.Journal of thrombosis and haemostasis : JTH · 2022Article
- Cardiovascular Disease in Myeloproliferative Neoplasms:JACC. CardioOncology · 2022Review
- MPN and thrombosis was hard enough . . . now there's COVID-19 thrombosis too.Hematology. American Society of Hematology. Education Program · 2021Review
- Evidence-Based Minireview: Are DOACs an alternative to vitamin K antagonists for treatment of venous thromboembolism in patients with MPN?Hematology. American Society of Hematology. Education Program · 2021Review
- Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients.Blood cancer journal · 2021Article
- NK Cells in Myeloproliferative Neoplasms (MPN).Cancers · 2021Review
- Combined venous and arterial thrombosis revealing underlying myeloproliferative disorder in a young patient: a case report.Journal of medical case reports · 2021Article
- Molecular and functional characteristics of megakaryocytes and platelets in aging.Current opinion in hematology · 2020Review
- Investigation and management of erythrocytosis.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2020Review
- Deep vein thrombosis: a less noticed complication in hematologic malignancies and immunologic disorders.Journal of thrombosis and thrombolysis · 2020Review
- Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper.Blood cancer journal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In myeloproliferative neoplasms (MPNs) the incidence of venous thromboembolism (VTE) is 0.6-1.0 per 100 pt-years, and the rate of recurrence after VTE is 6.0-6.5 per 100 pt-yrs. Vitamin K-antagonists (VKA) reduces the risk of recurrence after VTE at usual sites (i.e., deep venous thrombosis (DVT) of the legs and pulmonary embolism (PE)) by 48-69%, with a rate of recurrent thrombosis per 100 pt-yrs of 3.4-4.7 on VKA and 8.9-9.6 off VKA; VKA discontinuation produces a 2.2-fold increased risk of novel thrombotic events with respect to continuation. However, the rate of both recurrent thrombosis and major bleeding on VKA is higher in MPN patients than in non-MPN patients, and the risk-benefit balance of long-term VKA treatment is challenging. In the absence of strong evidence, the tailored management of MPN-related VTE should operatively consider the risk categories for recurrence and bleed well established in the non-MPN setting. In summary, MPN patients with VTE are candidates for life-long VKA treatment, especially after unprovoked proximal DVT and PE. Aspirin can offer a moderate benefit in those patients who stop anticoagulation. The use of direct oral anticoagulants should be explored aiming to ameliorate the rate of bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.